Skip to content
chikungunya
-
ANVISA grants marketing authorization for Valneva’s Ixchiq in Brazil
The vaccine is also approved for adolescents aged 12 and older in the European Union, and ongoing applications are being made to extend this label to adolescents in the US, Canada, and the UK.